Factor B inhibitor iptacopan, and factor D inhibitor danicopan have been shown to improve anemia and reduce hemolysis and transfusion needs in PNH patients who are suboptimal responders to anti-C5 in early phase trials (59, 60). This evidence concerns the gene C5 and anemia.